Optimised affinity purification of polyclonal antibodies from hyper immunised ovine serum using a synthetic Protein A adsorbent, MAbsorbent® A2P

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 814, Issue 2, 2005, Pages 209-215

  Newcombe, Anthony R ^a   Cresswell, Chrissie ^a   Davies, Susannah ^a   Watson, Keith ^b   Harris, Guy ^b   O'Donovan, Kieran ^a   Francis, Richard ^a  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

^b ProMetic Life Sciences Inc   (Canada)

Author keywords

Affinity purification; Antibody; Chromatography; Mimetic; Protein A; Serum

Indexed keywords

IMMUNOGLOBULIN; LIGANDS; SERUM; SYNTHETIC PROTEIN;

ADSORBENTS; CHROMATOGRAPHY; IMMUNIZATION; OPTIMIZATION; PRECIPITATION (CHEMICAL); PROTEINS; PURIFICATION; SODIUM COMPOUNDS;

ANTIBODIES;

ADSORBENT; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; PROTEIN A; SODIUM SULFATE;

ADSORPTION; AFFINITY CHROMATOGRAPHY; ANTIBODY AFFINITY; ARTICLE; DILUTION; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; SHEEP;

ANIMALS; ANTIBODIES; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; IMMUNE SERA; ISOELECTRIC FOCUSING; SHEEP; STAPHYLOCOCCAL PROTEIN A;

OVIS;

EID: 11844301298     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2004.10.027     Document Type: Article

References (20)

1. A.C. Roque, C.R. Lowe, and M.A. Taipa Biotechnol. Prog. 20 2004 639
2. CroFab, an antigen-binding fragment (Fab) antivenom of ovine origin, has been approved by the FDA for treatment of North American rattlesnake envenomation, Med. Lett. 1107 (2001) 55.
3. Y. Echelard, and H. Meade Nat. Biotechnol. 20 9 2002 881
4. E. Stoger, M. Sack, R. Fischer, and P. Christou Curr. Opin. Biotechnol. 13 2002 161
5. L.M. Houdebine Curr. Opin. Biotechnol. 13 2002 625
6. J.M. Robl, P. Kasinathan, E. Sullivan, Y. Kuroiwa, K. Tomizuka, and I. Ishida Theriogenology 59 2003 107
7. A.J. Racher, J.M. Tong, and J. Bonnerjea Biotechnology. Recombinant Proteins vol. 5a 2003 Wiley-VCH Weinheim, Germany p. 247
8. L. Guerrier, P. Girot, W. Schwartz, and E. Boschetti Bioseparation 9 2000 211
9. A. Verdoliva, F. Pannone, M. Rossi, S. Catello, and V. Manfredi J. Immunol. Methods 271 2002 77
10. S. Kabir Immunol. Invest. 31 2002 263
11. R. Li, V. Dowd, D.J. Stewart, S.J. Burton, and C.R. Lowe Nat. Biotechnol. 16 1998 190
12. D.K. Follman, and R.L. Fahrner J. Chromatogr. A 1024 2004 79 85
13. R.M. Baker, A.M. Brady, and B.S. Cambridge D.L. Pyle Separation for Biotechnology vol. 3 1994 Royal Society of Chemistry Cambridge, UK 427
14. P.A. Zunszain, P.A.J. Ghuman, T. Komatsu, E. Tsuchida, and S. Curry BMC Struct. Biol. 3 2003 6
15. S. Curry, S.P. Brick, and N.P. Franks Biochim. Biophys. Acta 1441 1999 131
16. D. Josić, and Y.-P. Lim Food Technol. Biotechnol. 39 2001 215
17. K. Mortelmans, and E. Zeiger Mutat. Res. 455 2000 29 60
18. M.C. dos Santos, M.R. D'Imperio Lima, G.C. Furtado, G.M. Colletto, T.L. Kipnis, and W. Dias da Silva Toxicon 27 1989 297
19. Medicines Control Agency, Rules and Guidance for Pharmaceutical Manufacturers and Distributors, TSO Press, Norwich, UK, 2002 (http://www.mhra.gov.uk).
20. FDA Code of Federal Regulations (CFR), Title 21 Food and Drugs, National Archives and Records Administration, Office of the Federal Register, USA, 2004 (http://www.fda.gov).